• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Scientists develop nanoparticles to ‘suffocate’ tumor cells

January 23, 2017 By Sarah Faulkner

Scientists develop nanoparticles to 'suffocate' tumor cellsA team of researchers from the Shanghai Institute of Ceramics, Chinese Academy of Sciences and the East China Normal University have developed polyvinyl pyrrolidone modified nanoparticles that serve as a deoxygenation agent against tumor cells. The therapy, which is described in Nature Nanotechnology, targeted cancer cells by cutting off the tumor’s blood supply to deprive and ‘suffocate’ tumor cells.

The agent is sensitive to changes in acid levels in the bloodstream, efficiently consumes oxygen and could create a product to aggregate and potentially block blood vessels, the team wrote. Preliminary work in mice models showed that the agent is biocompatible and establishes tumor hypoxia.

The team’s work demonstrated that the nanoparticles had very little cytotoxicity until they came upon the acidic environment of the cancer cell. In other words, the therapy effectively targeted cells and localized treatment to the area of the tumor.

In vivo studies in mice models showed that the nanoparticles are efficient deoxygenation agents – after 10 minutes, blood oxygen saturation levels did not change in control tumors, but drastically reduced in the test group. The team pointed out that imaging revealed that hypoxia occurred within the tumor and not in the surrounding tissue.

Compared to the control tumors, the cells that received the nanoparticle-based treatment demonstrated a slower growth rate and the cells had evidence of fibrosis, necrosis and apoptosis.

The team suggested that further work should be done to explore surface modifications to the nanoparticles, hypothesizing that researchers could customize the length of time the nanoparticles travel through the blood stream.

Filed Under: Featured, Nanoparticles, Oncology, Research & Development

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS